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Abstract
Transforming growth factor (TGF)-L receptor type II gene (Tgfbr2) knockout and wild type mice underwent chronic
estrogen exposure using estradiol pellets. Histological examination of the pituitary glands found 38 adenomas in 14
Tgfbr2(+/3) mice but only one tumor in ten wild type mice. Pituitary tumorigenesis is greatly accelerated in Tgfbr2(+/3)
mice by estrogen treatment. z 1998 Elsevier Science B.V. All rights reserved.
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Induction of pituitary tumor by the administration
of estrogen is well established, but the molecular tar-
gets of the estrogen-estrogen receptor complex in the
estrogen-dependent pituitary tumor are still not
known [1]. Identi¢cation of the critical genes and
the products that are involved in estrogen-induced
pituitary tumor will help to determine whether sim-
ilar genes are involved in human estrogen-induced
tumors. There are some strain and species di¡erences
in the response to estrogen, and a few strains of mice
such as C57 are refractory. Pituitary tumors develop
at a high frequency in p27-knockout mice [2^4] and
retinoblastoma (Rb) gene-knockout mice [5], which
suggests that cell cycle regulatory genes are involved
in the tumorigenesis of pituitary adenoma. We pre-
viously reported vast di¡erences in the expression of
TLR-II and p27 at the protein and mRNA levels in
human pituitary adenomas, although no gene muta-
tion or deletion was detected [6^8].
Estrogen-induced tumorigenesis in the anterior pi-
tuitary gland is associated with substantially reduced
expression of both TGF-L1 and Tgfbr2 [9]. TGF-L
stimulation causes the down-regulation of p27 ex-
pression [10], and also leads to inhibition of Rb
phosphorylation [11]. Therefore, TGF-L-mediated
signals can a¡ect both p27 and Rb expression. The
transmission of signals from TGF-L1 into cells re-
quires the formation of the heterometric complexes
of TGF-L receptor type I (TLR-I) and TGF-L recep-
tor type II (TLR-II) [12]. Signals from TGF-L1 can-
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not be transmitted if either or both of these receptors
are abnormal. The present study was undertaken to
examine whether TGF-L-mediated signals are in-
volved in the development of estrogen-induced pitui-
tary tumors using the recently generated Tgfbr2(+/3)
C57 mouse.
The homozygous Tgfbr2(3/3) mouse dies at
about 10.5 days after gestation because of defects
in the yolk sac hematopoiesis and vasculogenesis,
whereas heterozygous knockout mice are develop-
mentally normal [13]. Administration of estrogen to
Tgfbr2(+/3) mice was expected to cause marked re-
duction of Tgfbr2 expression, thus providing an ideal
model of absent Tgfbr2 expression during the tu-
morigenesis of estrogen-induced pituitary adenomas.
Either 1.5 mg (90 day release form) or 15 mg
(60 day release form) estradiol pellets (Innovative
Research of America, Sarasota, FL, USA) were sub-
cutaneously implanted in both female Tgfbr2(+/3)
C57BL/6J mice (6^8 weeks of age) and female
C57BL/6J mice (6^8 weeks of age) as controls.
DNA samples were obtained from the mouse tails
after birth to verify the genotype. Placebo pellets
(Innovative Research of America) were also subcuta-
neously implanted in four C57BL/6J mice.
Sequential changes of the plasma estradiol (E2)
concentration were measured by solid-phase 125I ra-
dioimmunoassay using a coat-A-count estradiol kit
(DPC, Los Angeles, CA, USA). After 30, 60 and
90 days of 1.5 mg estrogen pellet implantation, plas-
ma E2 was 906 pg/ml, 365 pg/ml and 81 pg/ml, re-
spectively. After 30 and 60 days of 15 mg estrogen
pellet implantation, plasma E2 was 3290 pg/ml and
2170 pg/ml, respectively.
Two thirds of the estrogen-treated mice survived
for more than 100 days but only one mouse survived
for more than 200 days. The major cause of death
was urine retention, probably due to the K-stimulat-
ing action of estrogen, associated with extreme hy-
dronephrosis. A few mice died of pyometra.
The pituitary glands were removed and ¢xed in
10% neutral bu¡ered formalin at 4‡C for one night
and then embedded in para⁄n. Serial sections of
3 Wm thickness were cut from the para⁄n block.
Fig. 1. Pituitary gland from a Tgfbr2(+/3) mouse which survived treatment with 15 mg estradiol for 208 days. (a) Macroscopic ap-
pearance of the markedly enlarged pituitary gland. (b) Macroscopic appearance of a horizontal section of the pituitary gland. (T1)
Hematoxylin and eosin staining of an adenoma originating from the anterior lobe. Bar = 45 Wm. (T3) Hematoxylin and eosin staining
of an adenoma originating from the intermediate lobe. Bar = 45 Wm. T1, tumor 1; T2, tumor 2; T3, tumor 3; PL, posterior lobe.
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Every 20th section was stained with hematoxylin and
eosin. The rest of the sections were used for immu-
nohistochemical staining by the ABC method using
the following primary polyclonal antibodies: anti-
adrenocorticotropic hormone (ACTH) antibody
(DAKO, Glostrup, Denmark), anti-prolactin (PRL)
antibody (UCB, Poole, UK), anti-growth hormone
(GH) antibody (Chemicon, Temecula, CA, USA),
anti-thyroid-stimulating hormone (TSH) antibody
(UCB), anti-luteinizing hormone antibody (UCB),
anti-follicle-stimulating hormone antibody (UCB),
anti-L-endorphin antibody (UCB) and anti-K-MSH
antibody (UCB).
Macroscopic tumor was found in only one
Tgfbr2(+/3) mouse which had a 15 mg estrogen pel-
let implanted for 208 days. This mouse harbored
three macroscopic tumors, two originating from the
lateral wing of the anterior lobe, and one from the
intermediate lobe (Fig. 1). The bilateral adrenal
glands were enlarged and histological examination
revealed adrenocortical hyperplasia.
Microscopic tumors were found in 13 Tgfbr2(+/3)
mice with 1.5 mg estrogen pellets implanted for a
mean period of 17.8 weeks. These mice harbored a
total of 36 tumors. In contrast, only one microscopic
tumor was observed in the ten control mice with
1.5 mg estrogen pellets implanted for a mean period
of 18.5 weeks (Table 1). Six microscopic tumors were
found in seven Tgfbr2(+/3) mice with 15 mg estro-
gen pellets implanted for a mean period of 17.7
weeks, and two microscopic tumors in three 15 mg
estrogen-treated control mice with 15 mg estrogen
pellets implanted for a mean period of 14.6 weeks.
Larger amounts of estrogen had no remarkable e¡ect
on pituitary tumorigenesis. No microscopic tumor
was observed in the control mice implanted with
placebo.
The 44 adenomas in the Tgfbr2(+/3) mice showed
immunohistochemical localization for PRL in 29 tu-
mors, PRL and TSH in seven, PRL and GH in four,
ACTH in three, and PRL, GH, and TSH in one.
Three adenomas showed immunohistochemical local-
ization not only for ACTH, but also for L-endorphin
and K-MSH, which is suggestive of an origin in the
intermediate lobe. All three adenomas in the control
mice showed immunohistochemical localization only
for PRL.
DNA was extracted from para⁄n-embedded mac-
roscopic tumor tissue and neighboring pituitary tis-
sue to investigate Tgfbr2 expression in normal pitui-
tary gland and macroscopic tumor. Ampli¢cation of
Tgfbr2 used PCR primer pairs designed according to
Table 1
Occurrence of pituitary tumorigenesis after continuous chronic estradiol treatment in Tgfbr2(+/3) mice and control mice
Duration of E2 treatment (weeks) Number of microscopically veri¢ed tumors/numberof mice examined
Control
E2:1.5 mg
Control
E2: 15 mg
Tgfbr2(+/3)
E2: 1.5 mg
Tgfbr2(+/3)
E2: 15 mg
8 0/1 0/1
10 1/1
11 0/1
12 0/1 6/2
13 0/1
14 2/2
15 0/1 2/1 0/1
16 0/1 1/1
17 0/1 0/1
18 0/1 2/2
19 0/1 2/1
20 0/2 2/1 1/1
21 2/1 1/1
22 1/2
23 5/2
25 16/1
29 3a/1
aMacroscopic tumors.
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the genomic sequences of Tgfbr2 as follows: TLR-F:
5P-TCCACCGGCAGCAGAAG-3P, TLR-R: 5P-CC-
CTGTGAACAATGGGCATCT-3P (564 bp). Glyc-
eraldehyde-3-phosphate dehydrogenase (G3PDH)
was used as a control: F: 5P-ACCACAGTCCAT-
GCCATCAC-3P, R: 5P-TCCACCACCCTGTTGC-
TGTA-3P (452 bp). Allele-speci¢c PCR was also per-
formed using the following primer sets: L-F: 5P-T-
GATTATGGACTTGCTTCCCGGTA-3P from the
intron 3 sequence and L-R: 5P-CGAAGTCACA-
CAGGCAACAGGTCA-3P from the coding se-
quence of exon 4 corresponding to codons 391^398
to detect the wild allele, and PKG-R: 5P-CTA-
AAGCGCATGCTCCAGACT-3P from the PKG
promoter sequence with L-F to detect the targeted
allele. PCR ampli¢cation (50 cycles) was performed
using a cycle of 1 min at 93‡C, 1 min at 53‡C or
59‡C, and 1 min at 72‡C using a programmable ther-
mal cycler (P-800, Astec, Japan).
PCR-ampli¢ed product solution was mixed with
the same amount of loading solution and electro-
phoresed using Mupid-2 (Cosmo Bio, Tokyo, Japan)
on 1.5% agarose gel containing ethidium bromide.
After electrophoresis, the bands were visualized
with a UV transilluminator and photographed.
PCR products of G3PDH were detected from pitui-
tary gland of both wild type and Tgfbr2(+/3) mice,
normal pituitary tissue after 29 week estrogen expo-
sure, and pituitary macroadenoma. PCR products of
Tgfbr2 were detected from pituitary gland of both
wild type and Tgfbr2(+/3) mice, but not from pitui-
tary tissue after 29 week estrogen exposure or from
pituitary macroadenoma (Fig. 2).
This study found that the rate of formation of
estrogen-induced pituitary tumor is greatly acceler-
ated in Tgfbr2(+/3) mice compared with wild type
mice. Microscopic spontaneous pituitary tumor does
not occur in female C57BL/6J mice until 47^64
weeks [14^16]. Since all mice in this study died at
less than 47 weeks after continuous estrogen treat-
ment, the tumorigenesis was probably estrogen-in-
duced rather than spontaneous.
Investigation of estrogen receptor-K gene-dis-
rupted mice has revealed a marked reduction in
PRL mRNA and a decrease in lactotroph cell num-
ber [17]. Speci¢c binding sites of TGF-L1 were found
in lactotrophs in the rat anterior pituitary gland, and
this TGF L1 binding was reduced following estrogen
treatment. Therefore, pituitary tumorigenesis involv-
ing the estrogen-estrogen receptor complex can be
expected to have links to lactotrophs [18]. In this
study, 44 of the 47 estrogen-induced tumors were
related to PRL-producing tumor.
Estrogen-induced tumorigenesis causes substantial
reduction in the expression of both TGF-L1 and
Tgfbr2 in the anterior pituitary of F344 rats [9].
TLR-II has been shown to have classic tumor-
suppressor activity [19]. These observations suggest
that estrogen can stimulate lactotroph proliferation,
and may transform lactotrophs. The Tgfbr2(+/3)
mouse has a higher chance that increased prolifera-
tion of lactotrophs caused by estrogen treatment will
result in loss of this gene and formation of the
Tgfbr2(3/3) genotype. In this study, PCR ampli¢ca-
Fig. 2. (A) PCR analysis of DNA from various tissue samples
showing a 564 bp band for Tgfbr2 in normal pituitary gland of
wild type mouse (lane 1) and in pituitary gland from Tgfbr2(+/
3) mice (lane 2), but not in pituitary tissue adjacent to adeno-
ma after 29 week estradiol exposure (lane 3) and in pituitary
macroadenoma (lane 4). (B) A 452 bp band for G3PDH was
found in all lanes. Lanes: 1, normal pituitary gland of wild
type mouse; 2, pituitary gland from Tgfbr2(+/3) mice; 3, pitui-
tary tissue adjacent to adenoma after 29 week estradiol expo-
sure; 4, pituitary macroadenoma.
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tion of DNA extracted from both macroscopic tu-
mor and normal-like pituitary tissue surrounding the
tumor could not detect Tgfbr2. Estrogen-induced tu-
mor is clearly associated with reduced expression of
Tgfbr2, so Tgfbr2 is likely to be deeply involved in
estrogen-induced tumorigenesis. However, further
study is necessary to investigate other genes which
may interact in estrogen-induced tumorigenesis.
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